Full Text View
Tabular View
No Study Results Posted
Related Studies
Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice
This study has been completed.
Study NCT00007527   Information provided by Department of Veterans Affairs
First Received: December 29, 2000   Last Updated: January 20, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Opiate Dependence
Additional conditions recognized in this trial
Opioid-Related Disorders
More general conditions related to this trial
Disorders of Environmental Origin
Mental Disorders
Substance-Related Disorders
Interventions listed in this trial
naloxone
buprenorphine
More general drug interventions related to this trial
Analgesics
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Department of Veterans Affairs
National Institute on Drug Abuse (NIDA)
Reckitt and Colman


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services